FDA Guidance on CT Mgmt during COVID-19
Health Care, Pharma Industry, Strategic Planning
FDA issued this guidance to provide general considerations to assist sponsors in assuring the safety of trial participants, maintaining compliance with good clinical practice (GCP), and minimizing risks to trial integrity during the COVID-19 pandemic.
Related Education Resources.
All ResourcesThe Innovator's Prescription
Topic: Pharma Industry
Abstract
Members
Overview of DtP Models for Clinical Trials
Topic: Conference
Video
Members
EAP 105: Expanded Access Logistics
Topics: Additional Concepts, Closeout, EAP, Execution, Forecasting / Planning
Presentation
Members
